Vyome Holdings, Embryyo Technologies Partner on AI Medtech

Vyome Holdings Inc. and Embryyo Technologies have signed an MoU (Memorandum of Understanding) to jointly pursue the global artificial intelligence (AI)-enabled medical device market. The collaboration combines Vyome’s healthcare industry experience and resources with Embryyo’s medical technology capabilities to potentially produce and commercialize smart medical devices that improve disease management and treatment.

“Vyome’s vision is to partner with the smartest talent tackling the biggest healthcare markets along the US-India corridor and across our three pillars of pharma, AI, and medical devices. AI-enabled medical devices represent a large opportunity and the Embryyo team—helmed by Indian Institutes of Technology (IIT) alums—has been working in this sector for a decade. We will be working with them to identify the specific initiatives on which we will partner,” Vyome Holdings Chairman Krishna Gupta said.

As part of this partnership, Vyome Holdings and Embryyo Technologies will host a global AI-enabled medical device innovation forum for companies along the U.S.-India corridor. The MoU is non-binding and may be subject to other conditions.

“We are excited about this partnership with Vyome as we have a shared vision. We are currently developing a portfolio of transformative medical devices spanning interventional oncology, surgery, wearables, and drug delivery, and Vyome’s access to global capital markets and the U.S. healthcare ecosystem will accelerate our mission to push the frontiers of medicine and elevate standards of care in healthcare globally,” Embryyo Technologies Co-Founder/CEO Nishant Kumar stated.

Vyome is building the world’s premier platform spanning the U.S.-India innovation corridor. Based in Cambridge, Mass., Vyome is striving to leverage its clinical-stage assets to transform the lives of patients with immuno-inflammatory conditions.

Embryyo is a medical device innovation studio that specializes in unmet clinical need discovery and validation, ideation, IP creation, early-stage technology de-risking and medical device product development. Over the years, Embryyo has worked with a diverse global clientele including med-tech MNC’s, inventive clinicians, philanthropic institutions, category leading manufacturers and funded startups, helping them identify, invent and realize first-of-its-kind medical devices. The company has also created a strong internal pipeline of early-stage med-tech IP assets it currently is licensing and commercializing through global partners and collaborators.